Skip to main content

Table 4 Association between biochemical markers C1M, C2M, C3M, CRPM, and hsPRO-C2 and BML imaging features at baseline

From: Association of biochemical markers with bone marrow lesion changes on imaging—data from the Foundation for the National Institutes of Health Osteoarthritis Biomarkers Consortium

 

aSerum C1M

Serum C2M

Serum C3M

aSerum CRPM

Serum hsPRO-C2

BMLs

 Maximum size

aMultinomial logistic regression

0.98

P = 0.779

(0.84, 1.14)

1.28

P = 0.001

(1.10, 1.49)

aMultinomial logistic regression

1.01

P = 0.943

(0.85, 1.20)

 Number of subregions

1.16

P = 0.046

(1.00, 1.34)

1.00

P = 0.951

(0.85, 1.17)

1.25

P = 0.002

(1.08, 1.44)

1.02

P = 0.760

(0.89, 1.16)

1.00

P = 0.959

(0.84, 1.18)

aMultinominal logistic regression

 Maximum size

Ref

  

Ref

 

  0

  1

  2

  3

1.14 (0.81, 0.60), P = 0.456

1.21 (0.86, 1.70), P = 0.274

1.24 (0.86, 1.78), P = 0.244

  

1.25 (0.64, 2.47), P = 0.515

1.17 (0.59, 2.35), P = 0.641

1.27 (0.64, 2.52), P = 0.501

 
  1. BMLs, bone marrow lesions; OR, odds ratio; 95% CI, 95% confidence interval; C1M, C2M, C3M, serum type I, type II and type III collagen degradation mediated by matrix metalloproteinase (MMP) cleavage; hsPRO-C2, serum propeptide of type IIb collagen; CRPM, serum metabolite of C-reactive protein
  2. aMultinomial analysis conducted as proportionality of odds assumption was not satisfied